Implications and limitations of cellular reprogramming for psychiatric drug development

por Tobe, Brian T D, Brandel, Michael G, Nye, Jeffrey S, Snyder, Evan Y
Publicado 2013

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease

por Hager, Klaus, Baseman, Alan S, Nye, Jeffrey S, Brashear, H Robert, Han, John, Sano, Mary, Davis, Bonnie, Richards, Henry M
Publicado 2014

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-contro...

por Hager, Klaus, Baseman, Alan S., Nye, Jeffrey S., Brashear, H. Robert, Han, John, Sano, Mary, Davis, Bonnie, Richards, Henry M.
Publicado 2016

The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized con...

por Prins, Niels D, van der Flier, Wiesje A, Knol, Dirk L, Fox, Nick C, Brashear, H Robert, Nye, Jeffrey S, Barkhof, Frederik, Scheltens, Philip
Publicado 2014

Changes in γ-secretase activity and specificity caused by the introduction of consensus aspartyl protease active motif in Presenilin 1

por Carter, Donald B, Dunn, Edwige, Pauley, Adele M, McKinley, Denise D, Fleck, Timothy J, Ellerbrook, Brenda R, Stratman, Nancy C, Zhou, Xiangdong, Himes, Carol S, Nye, Jeffrey S, Tomasselli, Alfredo, Yan, Riqiang
Publicado 2008

ASCLD statement on volume of untested sexual assault evidence kits

por Sudkamp, Laura, Gamette, Matthew, Wickenheiser, Ray, Arnone, Brooke, Forry, Erin, Gamette, Matthew, Jackson, Linda, Dyas, Rita C., Burdett, Lisa, Houlihan, Bruce, McNair, Jennifer, Nye, Jeffrey, O’Neill, Scott, Scanlan, Timothy, Tessarolo, Tony, Westring, Christian, Byrd, John, Robertson, Ramona
Publicado 2020